Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany

Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The primary outcome was direct and indirect costs in patients with ALL/DLBCL/FL who received HSCT between 2010...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2019-01, Vol.8 (2), p.121-131
Main Authors: Mayerhoff, Lukas, Lehne, Moritz, Hickstein, Lennart, Salimullah, Tayyab, Prieur, Sigurd, Thomas, Simu K, Zhang, Jie
Format: Article
Language:English
Subjects:
Adult
Adults
Age
Chemotherapy
Child
Cost of Illness
Costs
Efficiency
Female
Germany
health economics
Health risk assessment
hematology
Hematopoietic Stem Cell Transplantation - economics
Hospitals
Humans
Insurance Claim Review
Leukemia
Lymphoma
Lymphoma, Follicular - therapy
Lymphoma, Large B-Cell, Diffuse
Male
Middle Aged
oncology
Patients
Pediatrics
Population
Quality
Retrospective Studies
Stem cells
Studies
Transplants & implants
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The primary outcome was direct and indirect costs in patients with ALL/DLBCL/FL who received HSCT between 2010 and 2014. Costs were evaluated two to four quarters before to eight quarters after HSCT. Among 258 patients with HSCT, direct costs were €290,125/patient (pediatric ALL), €246,266/patient (adult ALL), €230,399/patient (DLBCL/FL allogeneic) and €107,457/patient (DLBCL/FL autologous). Indirect costs with HSCT were €52,939/patient (adult ALL), €20,285/patient (DLBCL/FL allogeneic) and €29,881/patient (DLBCL/FL autologous). Direct and indirect costs associated with HSCT are substantial for patients with ALL, DLBCL and FL. Novel therapies that reduce HSCT use could reduce medical costs.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2018-0100